Skip to main content

Market Overview

Recap: Albireo Pharma Q1 Earnings


Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 60.43% year over year to ($2.23), which may not compared to the estimate of ($1.36).

Revenue of $1,549,000 higher by 171.75% from the same period last year, which beat the estimate of $1,030,000.


Albireo Pharma hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 07, 2020

Webcast URL:

Recent Stock Performance

Company's 52-week high was at $38.69

52-week low: $11.26

Price action over last quarter: Up 3.09%

Company Profile

Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.


Related Articles (ALBO)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at